211 related articles for article (PubMed ID: 7876104)
1. The hemoregulatory peptide N-acetyl-Ser-Asp-Lys-Pro is a natural and specific substrate of the N-terminal active site of human angiotensin-converting enzyme.
Rousseau A; Michaud A; Chauvet MT; Lenfant M; Corvol P
J Biol Chem; 1995 Feb; 270(8):3656-61. PubMed ID: 7876104
[TBL] [Abstract][Full Text] [Related]
2. Substrate dependence of angiotensin I-converting enzyme inhibition: captopril displays a partial selectivity for inhibition of N-acetyl-seryl-aspartyl-lysyl-proline hydrolysis compared with that of angiotensin I.
Michaud A; Williams TA; Chauvet MT; Corvol P
Mol Pharmacol; 1997 Jun; 51(6):1070-6. PubMed ID: 9187274
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin I-converting enzyme and metabolism of the haematological peptide N-acetyl-seryl-aspartyl-lysyl-proline.
Azizi M; Junot C; Ezan E; Ménard J
Clin Exp Pharmacol Physiol; 2001 Dec; 28(12):1066-9. PubMed ID: 11903317
[TBL] [Abstract][Full Text] [Related]
4. N-domain selectivity of angiotensin I-converting enzyme as assessed by structure-function studies of its highly selective substrate, N-acetyl-seryl-aspartyl-lysyl-proline.
Michaud A; Chauvet MT; Corvol P
Biochem Pharmacol; 1999 Mar; 57(6):611-8. PubMed ID: 10037445
[TBL] [Abstract][Full Text] [Related]
5. Catabolism of the hemoregulatory peptide N-Acetyl-Ser-Asp-Lys-Pro: a new insight into the physiological role of the angiotensin-I-converting enzyme N-active site.
Rousseau-Plasse A; Lenfant M; Potier P
Bioorg Med Chem; 1996 Jul; 4(7):1113-9. PubMed ID: 8831983
[TBL] [Abstract][Full Text] [Related]
6. RXP 407, a phosphinic peptide, is a potent inhibitor of angiotensin I converting enzyme able to differentiate between its two active sites.
Dive V; Cotton J; Yiotakis A; Michaud A; Vassiliou S; Jiracek J; Vazeux G; Chauvet MT; Cuniasse P; Corvol P
Proc Natl Acad Sci U S A; 1999 Apr; 96(8):4330-5. PubMed ID: 10200262
[TBL] [Abstract][Full Text] [Related]
7. In vivo assessment of captopril selectivity of angiotensin I-converting enzyme inhibition: differential inhibition of acetyl-ser-asp-lys-pro and angiotensin I hydrolysis.
Junot C; Menard J; Gonzales MF; Michaud A; Corvol P; Ezan E
J Pharmacol Exp Ther; 1999 Jun; 289(3):1257-61. PubMed ID: 10336514
[TBL] [Abstract][Full Text] [Related]
8. Involvement of human plasma angiotensin I-converting enzyme in the degradation of the haemoregulatory peptide N-acetyl-seryl-aspartyl-lysyl-proline.
Rieger KJ; Saez-Servent N; Papet MP; Wdzieczak-Bakala J; Morgat JL; Thierry J; Voelter W; Lenfant M
Biochem J; 1993 Dec; 296 ( Pt 2)(Pt 2):373-8. PubMed ID: 8257427
[TBL] [Abstract][Full Text] [Related]
9. RXP 407, a selective inhibitor of the N-domain of angiotensin I-converting enzyme, blocks in vivo the degradation of hemoregulatory peptide acetyl-Ser-Asp-Lys-Pro with no effect on angiotensin I hydrolysis.
Junot C; Gonzales MF; Ezan E; Cotton J; Vazeux G; Michaud A; Azizi M; Vassiliou S; Yiotakis A; Corvol P; Dive V
J Pharmacol Exp Ther; 2001 May; 297(2):606-11. PubMed ID: 11303049
[TBL] [Abstract][Full Text] [Related]
10. Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline.
Azizi M; Rousseau A; Ezan E; Guyene TT; Michelet S; Grognet JM; Lenfant M; Corvol P; Ménard J
J Clin Invest; 1996 Feb; 97(3):839-44. PubMed ID: 8609242
[TBL] [Abstract][Full Text] [Related]
11. Differences in the properties and enzymatic specificities of the two active sites of angiotensin I-converting enzyme (kininase II). Studies with bradykinin and other natural peptides.
Jaspard E; Wei L; Alhenc-Gelas F
J Biol Chem; 1993 May; 268(13):9496-503. PubMed ID: 7683654
[TBL] [Abstract][Full Text] [Related]
12. In vitro effect of acetyl-N-Ser-Asp-Lys-Pro (AcSDKP) analogs resistant to angiotensin I-converting enzyme on hematopoietic stem cell and progenitor cell proliferation.
Gaudron S; Grillon C; Thierry J; Riches A; Wierenga PK; Wdzieczak-Bakala J
Stem Cells; 1999; 17(2):100-6. PubMed ID: 10195570
[TBL] [Abstract][Full Text] [Related]
13. Structure-function analysis of angiotensin I-converting enzyme using monoclonal antibodies. Selective inhibition of the amino-terminal active site.
Danilov S; Jaspard E; Churakova T; Towbin H; Savoie F; Wei L; Alhenc-Gelas F
J Biol Chem; 1994 Oct; 269(43):26806-14. PubMed ID: 7523412
[TBL] [Abstract][Full Text] [Related]
14. Renal and metabolic clearance of N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) during angiotensin-converting enzyme inhibition in humans.
Azizi M; Ezan E; Reny JL; Wdzieczak-Bakala J; Gerineau V; Ménard J
Hypertension; 1999 Mar; 33(3):879-86. PubMed ID: 10082503
[TBL] [Abstract][Full Text] [Related]
15. The influence of angiotensin converting enzyme mutations on the kinetics and dynamics of N-domain selective inhibition.
Lubbe L; Sewell BT; Sturrock ED
FEBS J; 2016 Nov; 283(21):3941-3961. PubMed ID: 27636235
[TBL] [Abstract][Full Text] [Related]
16. Peptidase specificity characterization of C- and N-terminal catalytic sites of angiotensin I-converting enzyme.
Araujo MC; Melo RL; Cesari MH; Juliano MA; Juliano L; Carmona AK
Biochemistry; 2000 Jul; 39(29):8519-25. PubMed ID: 10913258
[TBL] [Abstract][Full Text] [Related]
17. Drosophila melanogaster angiotensin I-converting enzyme expressed in Pichia pastoris resembles the C domain of the mammalian homologue and does not require glycosylation for secretion and enzymic activity.
Williams TA; Michaud A; Houard X; Chauvet MT; Soubrier F; Corvol P
Biochem J; 1996 Aug; 318 ( Pt 1)(Pt 1):125-31. PubMed ID: 8761461
[TBL] [Abstract][Full Text] [Related]
18. A novel angiotensin I-converting enzyme mutation (S333W) impairs N-domain enzymatic cleavage of the anti-fibrotic peptide, AcSDKP.
Danilov SM; Wade MS; Schwager SL; Douglas RG; Nesterovitch AB; Popova IA; Hogarth KD; Bhardwaj N; Schwartz DE; Sturrock ED; Garcia JG
PLoS One; 2014; 9(2):e88001. PubMed ID: 24505347
[TBL] [Abstract][Full Text] [Related]
19. Single-domain angiotensin I converting enzyme (kininase II): characterization and properties.
Deddish PA; Wang LX; Jackman HL; Michel B; Wang J; Skidgel RA; Erdös EG
J Pharmacol Exp Ther; 1996 Dec; 279(3):1582-9. PubMed ID: 8968386
[TBL] [Abstract][Full Text] [Related]
20. Selective inhibition of the C-domain of angiotensin I converting enzyme by bradykinin potentiating peptides.
Cotton J; Hayashi MA; Cuniasse P; Vazeux G; Ianzer D; De Camargo AC; Dive V
Biochemistry; 2002 May; 41(19):6065-71. PubMed ID: 11994001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
